comparemela.com

Latest Breaking News On - Intravenous aviptadil - Page 1 : comparemela.com

Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U S Na

Relief Therapeutics Holding SA / Key word(s): Miscellaneous31-May-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Provides a Corporate Update and Comments on the Recently Announced Data Safety Monitoring Board (.

Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U S National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients

Adhoc: Relief Therapeutics Holding SA: Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U S National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients

NRx Pharmaceuticals, Inc Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

Share this article Share this article RADNOR, Pa., May 25, 2021 /PRNewswire/ Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (Nasdaq:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of Bringing Hope to Life, said Professor Jonathan Javitt, MD, MPH, Founder, CEO and Chairman of the Board, of NRx. We are indebted to the leaders and shareholders of BRPA who have chosen to support our mission.  

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.